NASDAQ:EPZM - Epizyme Stock Price, Price Target & More

Sign in or create an account to add this stock to your watchlist.
$14.70 -0.15 (-1.01 %)
(As of 06/19/2018 02:00 PM ET)
Previous Close$14.85
Today's Range$14.55 - $14.95
52-Week Range$11.15 - $21.40
Volume9,908 shs
Average Volume396,657 shs
Market Capitalization$1.04 billion
P/E Ratio-6.68
Dividend YieldN/A
Beta2.09
Epizyme logoEpizyme, Inc., a clinical stage biopharmaceutical company, discovers and develops novel epigenetic medicines for patients with cancer and other diseases in the United States. Its product candidates include tazemetostat, an inhibitor of the EZH2, which is in Phase II clinical trial for patients with relapsed or refractory non-hodgkin lymphoma (NHL); Phase II clinical trial for relapsed or refractory patients with mesothelioma; Phase I dose-escalation and expansion study for children with INI1-negative solid tumors; Phase II clinical trials for patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL); Phase Ib/II clinical trial in elderly patients with DLBCL; and Phase II clinical trial for relapsed or refractory patients with mesothelioma characterized by BAP1 loss-of-function,; and Phase Ib/II clinical trial for the treatment of patients with relapsed or refractory metastatic non-small cell lung cancer, as well as Phase II clinical trial in adult patients with ovarian cancer. The company is also developing additional programs, such as pinometostat, an intravenously administered small molecule inhibitor of DOT1L for the treatment of acute leukemias; and PRMT5 inhibitor that is in Phase I clinical trial for patients with solid tumors and NHL. It has collaboration agreements with Celgene Corporation, Genentech Inc., and Glaxo Group Limited, as well as with Roche Molecular Systems, Inc., Eisai Co. Ltd., and Lymphoma Study Association. Epizyme, Inc. was founded in 2007 and is headquartered in Cambridge, Massachusetts.

Receive EPZM News and Ratings via Email

Sign-up to receive the latest news and ratings for EPZM and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:EPZM
CUSIPN/A
Phone617-229-5872

Debt

Debt-to-Equity RatioN/A
Current Ratio10.43
Quick Ratio10.43

Price-To-Earnings

Trailing P/E Ratio-6.68
Forward P/E Ratio-6.62
P/E GrowthN/A

Sales & Book Value

Annual Sales$10 million
Price / Sales102.15
Cash FlowN/A
Price / CashN/A
Book Value$3.40 per share
Price / Book4.32

Profitability

EPS (Most Recent Fiscal Year)($2.18)
Net Income$-134,300,000.00
Net MarginsN/A
Return on Equity-61.42%
Return on Assets-50.53%

Miscellaneous

Employees131
Outstanding Shares69,490,000

Epizyme (NASDAQ:EPZM) Frequently Asked Questions

What is Epizyme's stock symbol?

Epizyme trades on the NASDAQ under the ticker symbol "EPZM."

How were Epizyme's earnings last quarter?

Epizyme Inc (NASDAQ:EPZM) issued its quarterly earnings data on Tuesday, May, 8th. The biopharmaceutical company reported ($0.49) EPS for the quarter, beating the consensus estimate of ($0.54) by $0.05. During the same period last year, the business earned ($0.56) earnings per share. View Epizyme's Earnings History.

When is Epizyme's next earnings date?

Epizyme is scheduled to release their next quarterly earnings announcement on Thursday, August, 2nd 2018. View Earnings Estimates for Epizyme.

What price target have analysts set for EPZM?

10 brokers have issued 1 year price objectives for Epizyme's shares. Their forecasts range from $16.00 to $26.00. On average, they anticipate Epizyme's stock price to reach $23.10 in the next twelve months. View Analyst Ratings for Epizyme.

What are Wall Street analysts saying about Epizyme stock?

Here are some recent quotes from research analysts about Epizyme stock:
  • 1. HC Wainwright analysts commented, "We believe EPZM’s trial is no exception. As far as we know, BAP1 loss is more frequently associated with peritoneal MM while pleural MM is the most prevalent (~80%), and is also more frequently associated with MM of epitheliod origin (~88% of patients in this study). Thus, it is almost impossible to extrapolate the potential survival benefit from this specific patient group without a properly controlled, well matched placebo arm. We believe such a trial at most serves to provide depth with respect to the human PK/PD for tazemetostat, proof of concept for clinical activity and potentially to point to patient subpopulations with enriched efficacy signals." (5/21/2018)
  • 2. According to Zacks Investment Research, "Epizyme reported narrower than expected loss in the fourth quarter of 2017. Epizyme's efforts on developing its lead candidate, tazemetostat, for a number of hematological malignancies and genetically defined solid tumors are impressive. During the fourth quarter of 2017, the company had a productive interaction with the FDA to design the registration strategy for tazemetostat for epithelioid sarcomaand follicular lymphoma (FL) and identified a path to submit for accelerated approval for both the indications. The company plans to file a first new drug application of tazemetostat for epithelioid sarcoma in fourth quarter of 2018 and second NDA for FL in 2019. A potential approval for the candidate will be a significant boost for the company. So far this year, Epizyme’s share price has also outperformed the industry. However, the company is highly dependent on its collaboration partners for top-line growth with no approved product." (3/16/2018)
  • 3. Cann analysts commented, "Epizyme presented two posters at the American Society of Hematology Meeting on December 10-11, 2017. These included a biomarker study in non-Hodgkin’s lymphoma (NHL) and preliminary response data from the diffuse large B cell lymphoma (DLBCL) cohort from the ongoing phase II study of tazemetostat in NHL. The data presented is very supportive of our outlook." (12/12/2017)

Who are some of Epizyme's key competitors?

Who are Epizyme's key executives?

Epizyme's management team includes the folowing people:
  • Mr. Robert B. Bazemore Jr., Pres, CEO, Sec. & Director (Age 50)
  • Dr. H. Robert Horvitz Ph.D., M.D., Co-Founder and Chairman of the Scientific Advisory Board
  • Dr. Yi Zhang Ph.D., Scientific Co-Founder and Member of The Scientific Advisory Board
  • Mr. Matthew E. Ros, Chief Operating Officer (Age 51)
  • Dr. Michael Boretti, VP of Bus. Devel.

Has Epizyme been receiving favorable news coverage?

Media coverage about EPZM stock has trended somewhat positive recently, Accern Sentiment reports. The research group identifies positive and negative news coverage by analyzing more than 20 million news and blog sources. Accern ranks coverage of public companies on a scale of negative one to one, with scores nearest to one being the most favorable. Epizyme earned a news sentiment score of 0.07 on Accern's scale. They also assigned headlines about the biopharmaceutical company an impact score of 45.44 out of 100, meaning that recent news coverage is somewhat unlikely to have an effect on the stock's share price in the next several days.

Who are Epizyme's major shareholders?

Epizyme's stock is owned by many different of institutional and retail investors. Top institutional shareholders include Palo Alto Investors LP (9.92%), BlackRock Inc. (5.61%), Redmile Group LLC (2.90%), Rock Springs Capital Management LP (1.83%), Millennium Management LLC (1.23%) and Point72 Asset Management L.P. (1.08%). Company insiders that own Epizyme stock include Andrew E Singer, David M Mott, Matthew Ros, Peter Tai-Ching Ho and Robert A Copeland. View Institutional Ownership Trends for Epizyme.

Which major investors are selling Epizyme stock?

EPZM stock was sold by a variety of institutional investors in the last quarter, including Millennium Management LLC, BlackRock Inc., University of Notre Dame DU Lac, Citigroup Inc., Rock Springs Capital Management LP, Barclays PLC and Teacher Retirement System of Texas. Company insiders that have sold Epizyme company stock in the last year include Andrew E Singer, Matthew Ros and Peter Tai-Ching Ho. View Insider Buying and Selling for Epizyme.

Which major investors are buying Epizyme stock?

EPZM stock was bought by a variety of institutional investors in the last quarter, including Point72 Asset Management L.P., JPMorgan Chase & Co., UBS Group AG, Redmile Group LLC, Sio Capital Management LLC, Opaleye Management Inc., Thrivent Financial for Lutherans and Eversept Partners LLC. View Insider Buying and Selling for Epizyme.

How do I buy shares of Epizyme?

Shares of EPZM can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Epizyme's stock price today?

One share of EPZM stock can currently be purchased for approximately $14.70.

How big of a company is Epizyme?

Epizyme has a market capitalization of $1.04 billion and generates $10 million in revenue each year. The biopharmaceutical company earns $-134,300,000.00 in net income (profit) each year or ($2.18) on an earnings per share basis. Epizyme employs 131 workers across the globe.

How can I contact Epizyme?

Epizyme's mailing address is 400 TECHNOLOGY SQUARE, CAMBRIDGE MA, 02139. The biopharmaceutical company can be reached via phone at 617-229-5872 or via email at [email protected]


MarketBeat Community Rating for Epizyme (EPZM)

Community Ranking:  3.0 out of 5 (star star star)
Outperform Votes:  313 (Vote Outperform)
Underperform Votes:  204 (Vote Underperform)
Total Votes:  517
MarketBeat's community ratings are surveys of what our community members think about Epizyme and other stocks. Vote "Outperform" if you believe EPZM will outperform the S&P 500 over the long term. Vote "Underperform" if you believe EPZM will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 6/19/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.